Ayala Pharmaceuticals, Inc. ADXS
At closeFeb 4, 2026, 4:00 PM EST
- YTD
- +1,405.11%
- 1 year
- +2,014.01%
- Market cap
- 25.71M
- Revenue (ttm)
- 3.24M
- EPS (ttm)
- -7.99
- Shares out
- 145.64M
- P/E ratio
- -0.08
- Forward P/E
- -1.03
- YTD return
- +1405.11%
- 1-year return
- +2014.01%
- Volume
- 10.01K
- Avg volume
- 5.05K
- Open
- 0.0996
- Previous close
- 0.60355
- Day's range
- 0.0846 – 0.60355
- 52-week range
- 0.0011 – 0.801
- Beta
- 2.05
- Analysts
- Buy
- Earnings date
- Feb 19, 2024
2Y +0.5766 (+2135.56%)
Key statistics
- Enterprise value
- -21.95M
- PEG ratio
- 0.00
- Price / sales
- 6.97
- Price / book
- 0.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.02M
- Total cash
- 45.26M
- Total debt
- 0
- Return on equity
- -49.85%
- Short % of float
- 2.15%
- 50-day average
- 0.31906
- 200-day average
- 0.445205
Analyst view
Consensus: buy
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 19, 2024
Expected Feb 19, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 19, 2024 | Jan 1, 2024 | 0.00 | — | — | — |
| May 4, 2023 | Jan 1, 2023 | 0.00 | — | — | — |
| Sep 12, 2022 | Jul 1, 2022 | 0.00 | -3.83 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2020 | H.C. Wainwright | down | Buy | Neutral |
| Nov 25, 2020 | Jefferies | down | Buy | Hold |
| Nov 25, 2020 | H.C. Wainwright | main | Buy | Buy |
| Nov 25, 2020 | Cantor Fitzgerald | main | Overweight | Overweight |
| Nov 25, 2020 | Barclays | main | — | Overweight |
| Nov 25, 2020 | Barclays | main | — | Overweight |
About Ayala Pharmaceuticals, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- advaxis.com
News
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023 
38 Stocks Moving In Thursday's Mid-Day Session 
50 Biggest Movers From Yesterday - 35 Stocks Moving In Wednesday's Mid-Day Session
30 Stocks Moving in Friday's Pre-Market Session - 12 Health Care Stocks Moving In Wednesday's Intraday Session
101 Biggest Movers From Friday - 66 Stocks Moving In Friday's Mid-Day Session
- 80 Biggest Movers From Yesterday
48 Stocks Moving In Monday's Mid-Day Session
Your note
Sign in to keep a note on ADXS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPEL RONI A | Director | Sale | Mar 12, 2020 | 0 |
| BERLIN KENNETH A | Chief Executive Officer | Stock Award(Grant) | Apr 7, 2019 | 4,000 |
| BERMAN RICHARD J | Director | Stock Award(Grant) | Jun 25, 2018 | 55,669 |
| BONSTEIN SARA M | Chief Financial Officer | Stock Award(Grant) | Mar 28, 2018 | 226,670 |
| GUTIERREZ ANDRES A. | Officer | Stock Award(Grant) | Apr 10, 2019 | 3,750 |
| HENDERSON MOLLY | Chief Financial Officer | Stock Award(Grant) | Apr 10, 2019 | 5,833 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 4.09% | 5,957,642 | 3.11M | Sep 29, 2021 |
| Blackrock Inc. | 0.86% | 1,257,252 | 655.66K | Sep 29, 2021 |
| Geode Capital Management, LLC | 0.78% | 1,135,533 | 592.18K | Sep 29, 2021 |
| State Street Corporation | 0.26% | 385,064 | 200.81K | Sep 29, 2021 |
| Northern Trust Corporation | 0.17% | 252,877 | 131.88K | Sep 29, 2021 |
| Millennium Management LLC | 0.17% | 244,970 | 127.75K | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.82% | 4,102,475 | 2.14M | Sep 29, 2021 |
| Vanguard Extended Market Index Fund | 1.14% | 1,663,811 | 867.68K | Sep 29, 2021 |
| Fidelity Extended Market Index Fund | 0.52% | 753,761 | 365.27K | Oct 30, 2021 |
| Price (T.Rowe) U.S. Equities Trust | 0.11% | 166,748 | 86.96K | Sep 29, 2021 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.11% | 159,787 | 77.43K | Oct 30, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.09% | 132,082 | 64.01K | Oct 30, 2021 |